eFFECTOR Therapeutics Inc at JMP Securities Life Sciences Conference Transcript
Welcome, eFFECTOR Therapeutics. Here on stage with me is Steve Worland, President and CEO; and Mike Byrnes, CFO. As I've mentioned to you guys, I never know exactly who's in the audience who wants a filtering in and whether they know the eFFECTOR Therapeutics story. So if you could just, in two to five minutes, take us through what eFFECTOR is about, that would be great.
Yeah, sure, Ren. Happy to start with that, and I really appreciate the opportunity to be here today. So eFFECTOR is a clinical-stage company. We have two assets in Phase 2 clinical trials. The targets work -- or I mean, excuse me -- the drug candidates work by blocking a network of proteins required for cancer survival and proliferation, as well as immune evasion.
The lead asset is tomivosertib or we call that tomi for short. That's in a randomized Phase 2b study right now. And the second asset is zotatifin, or zota for short, is in an expansion cohort sort of Phase 2a study right now.
The overall
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |